About Bionor Holding
Bionor Holding is a company based in Oslo (Norway) founded in 1985. It operates as a B2B and Research and Development. Bionor Holding has completed 1 acquisition, including Solon Eiendom. Bionor Holding offers products and services including Vacc-4x, Vacc-C5, and CRX. Bionor Holding operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Oslo, Norway
- SectorsHealthcare
- Website bionorholding.com
- Social X
- Legal Name Bionor Holding As
- Investments & Acquisitions
Products & Services of Bionor Holding
Bionor Holding offers a comprehensive portfolio of products and services, including Vacc-4x, Vacc-C5, and CRX.
Vaccine for functional HIV cure via immune system enhancement.
Part of combination therapy targeting HIV cure mechanisms.
Provides neutralizing properties for Bionor's HIV program strategy.
Investments & Acquisitions by Bionor Holding
Bionor Holding has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Solon Eiendom.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Residential properties are developed by Solon Eiendom in Norway. | soloneiendom.no | Oslo, Norway | 2008 | Nov 2016 | $115.99M |
Complete acquisition details for Bionor Holding
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bionor Holding
2 dated milestones of Bionor Holding across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Bionor Holding is founded.
- Acquisition Acquires Solon Eiendom.
Competitors of Bionor Holding
Bionor Holding operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection |
Detailed competitors of Bionor Holding
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bionor Holding
Complete news archive for Bionor Holding
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bionor Holding
10 companies that operate in the same segment as Bionor Holding (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bionor Holding
Bionor Holding was founded in 1985.
Bionor Holding is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Bionor Holding AS is a Norwegian biopharmaceutical company that advances proprietary therapeutic vaccines like Vacc-4x and Vacc-C5 to achieve a functional HIV cure. It focuses on combining vaccines with the immune system, having completed clinical trials and invested over USD 100 million in research. The company operates from Oslo, Norway, and leverages immunology expertise from its origins in Skien. Bionor targets viral diseases, particularly HIV, through peptide vaccine development and strategic acquisitions.
Bionor Holding's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Bionor Holding offers Vacc-4x, Vacc-C5, and CRX.
Bionor Holding has made 1 acquisition, including Solon Eiendom.
Bionor Holding operates through Bionor Holding As.